Obinutuzumab for connective tissue disease–related interstitial lung disease in adults
Official title: 2/2 Efficacy and Safety of Obinutuzumab in Connective Tissue Disease-Related Interstitial Lung Disease
Funded at Johns Hopkins University · NIH-11451395 · Data updated 2026-11-12
A study will test whether Obinutuzumab, given with standard treatments, can help adults with CTD-ILD breathe better and have fewer disease-related problems.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 3, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $1,446,483 |
| NIH project number | 1U24HL183678-01A1 |
| Project ID | NIH-11451395 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults (21+) with connective tissue disease–related ILD who are currently on mycophenolate and meet study criteria.
✕Less likely to help
Patients with CTD-ILD who do not respond to B cell–targeted therapy or who experience unacceptable side effects may not benefit.
What this research studies
This project is designed to determine if an anti-B cell therapy called Obinutuzumab can be effective and safe for adults with CTD-ILD who are on mycophenolate. It includes a two-phase plan: an initial planning phase to build the trial infrastructure, followed by a Phase II trial to evaluate treatment outcomes. Researchers will monitor B cell activity and adverse events while patients receive the therapy on a defined schedule. The aim is to generate high-quality evidence to guide future treatment decisions for CTD-ILD.
Why it matters
Potential benefit: If successful, patients with CTD-ILD could have access to a more effective treatment option that improves lung function and reduces disease activity.
How similar studies have gone: Evidence for anti-B cell therapy in CTD-ILD is promising but high-quality trial data are currently lacking; this study seeks to provide rigorous results.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Hanley, Daniel F — Johns Hopkins University
- Study coordinator: Hanley, Daniel F
Related research
Other NIH-funded projects on the same topics.
-
Obinutuzumab for CTD-Related Interstitial Lung Disease in adults
This project tests whether the anti-B cell therapy obinutuzumab can help adults with connective tissue disease–related ILD who are on mycophenolate therapy.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Understanding how a cell protein (SLC9A1) drives skin and lung scarring in systemic sclerosis
A five-year NIH grant aims to understand how a specific cell protein called SLC9A1 influences scar-forming cells in systemic sclerosis and related lung disease, with the goal of finding possible therapies.
-
From proteins and genes to new treatments for scar-related lung disease
A large NIH grant is working to map the proteins in the lungs of people with systemic sclerosis to find new targets for drugs that could slow or stop lung fibrosis.
-
Vasculopathy in Systemic Sclerosis and Lung Disease in Adults
A study in adults with systemic sclerosis will look at how blood vessels in the lungs and body relate to the development of lung disease, with the aim of finding new ways to prevent it.
-
Understanding why a rare pediatric lung disease happens and how to treat it
Aims to uncover the molecular causes of pediatric interstitial lung disease and use that knowledge to develop targeted therapies for children affected by this condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.